Martine Zimmermann
Director/Board Member chez INVENTIVA
Fortune : 181 315 $ au 29/02/2024
Profil
Presently, Martine Zimmermann holds the position of SVP, Head-Regulatory Affairs, R&D Quality at Ipsen Biopharmaceuticals, Inc. She is also on the board of Ligand Pharmaceuticals, Inc. and Inventiva SA.
Dr. Zimmermann previously held the position of Senior VP & Head-Global Regulatory Affairs at Alexion Pharmaceuticals, Inc.
She received a doctorate from Louis Pasteur University and a doctorate from the University of Strasbourg.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
22/09/2023 | 2 285 ( 0,01% ) | 181 315 $ | 29/02/2024 |
Postes actifs de Martine Zimmermann
Sociétés | Poste | Début |
---|---|---|
INVENTIVA | Director/Board Member | 16/04/2021 |
LIGAND PHARMACEUTICALS INCORPORATED | Director/Board Member | 26/09/2023 |
Ipsen Biopharmaceuticals, Inc. | General Counsel | - |
Anciens postes connus de Martine Zimmermann
Sociétés | Poste | Fin |
---|---|---|
ALEXION PHARMACEUTICALS, INC. | General Counsel | 01/02/2023 |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Director/Board Member | 01/01/2021 |
Formation de Martine Zimmermann
University of Strasbourg | Doctorate Degree |
Louis Pasteur University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
INVENTIVA | Health Technology |
Entreprise privées | 3 |
---|---|
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Ipsen Biopharmaceuticals, Inc. | |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Health Technology |